CELC (Celcuity) רווח נקי למניה (EPS TTM)

Celcuity Inc. operates in an R&D integration mode with pharmaceutical behemoths while awaiting FDA approval to launch commercial operations. The moving average of net income per share visualizes this lull period, where the metric value stands at -4.69. This price action relies on the success of clinical trials and expense control, although the risks of negative data and the complexities of implementing new analytical methods create financial uncertainty.

The non-cyclical nature of oncology diagnostics at Celcuity Inc. (CELC) ensures a stable cash flow, shielded from macroeconomic shocks by medical insurance. By analyzing the trailing twelve months (TTM) fundamental earnings per share, an investor tracks the rolling annual net income divided by the number of shares, which allows for an objective assessment of capital generation efficiency and the timely identification of a reversal in the long-term yield trend.